Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 3/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.36 |
| ▸ | TLR9 | Q9NR96 | 3/20 | 0.32 |
| ▸ | TLR8 | Q9NR97 | 3/20 | 0.32 |
| ▸ | TLR7 | Q9NYK1 | 3/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4866906 | 0.89 | KCNH2 (0.38) | KCNH2HRH3TLR9TLR8TLR7 | |
| SCHEMBL4875248 | 0.88 | PTGS2 (0.35) | KCNH2HRH3BRD4CREBBPPTGS2 | |
| SCHEMBL4875039 | 0.88 | KCNH2 (0.38) | KCNH2HRH3BRD4CREBBP | |
| SCHEMBL5225066 | 0.82 | KCNH2 (0.38) | KCNH2HRH3TLR9TLR8TLR7 | |
| SCHEMBL3931408 | 0.82 | KCNH2 (0.37) | KCNH2HRH3BRD4CREBBP | |
| SCHEMBL2994293 | 0.82 | EGFR (0.40) | BRD4 | |
| SCHEMBL4875180 | 0.81 | KCNH2 (0.38) | KCNH2HRH3BRD4CREBBP | |
| SCHEMBL4868675 | 0.81 | SMO (0.32) | BRD4CREBBPPTGS2 | |
| SCHEMBL5222056 | 0.80 | KCNH2 (0.37) | KCNH2HRH3TLR9TLR8TLR7 | |
| SCHEMBL4868423 | 0.80 | KCNH2 (0.37) | KCNH2HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080051384-A1 | ANTIVIRAL AGENTS | GENELABS TECHNOLOGIES, INC. | 2008-02-28 | — | — | US | disclosed |
| US-20080051384-A1 | ANTIVIRAL AGENTS | GENELABS TECHNOLOGIES, INC. | 2008-02-28 | — | — | US | disclosed |
| US-20080051384-A1 | ANTIVIRAL AGENTS | GENELABS TECHNOLOGIES, INC. | 2008-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051384-A1 | ANTIVIRAL AGENTS | EIF2AK2, MAVS, ZC3HAV1 | KCNH2 2647/4885HRH3 4258/4885TLR9 985/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.